Rare diseases
Investigational molecules
Locations
364 conditions with trials, the busiest first
1 201 trials across Europe, recruiting first
Study of Acalabrutinib and Rituximab for Elderly Patients with Untreated Mantle Cell Lymphoma
DenmarkStudy of Elranatamab for Patients with Multiple Myeloma Resistant to Proteasome Inhibitors, Immunomodulatory Drugs, and Anti-CD38 Antibodies
BelgiumStudy on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment
AustriaStudy of SY-1425 (tamibarotene) alone or with azacitidine in adult patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
FranceStudy of Obinutuzumab as First-Line Treatment for Adult Patients with Marginal Zone Lymphoma Who Are Not Eligible for Local Therapy
GermanyStudy of treatment discontinuation with nilotinib and asciminib in adults with chronic myeloid leukemia to achieve treatment-free remission
ItalyStudy on the Safety and Effects of Tolinapant in Patients with Advanced Solid Tumors and Lymphomas
ItalyStudy Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma
BelgiumStudy on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies
GermanyStudy on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease
DenmarkStudy Comparing Rituximab with Ibrutinib to Rituximab with Chemotherapy for Older Patients with Untreated Mantle Cell Lymphoma
DenmarkStudy on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse
GermanyThe therapies tested most often in Blood and lymphatic system disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
